Bio-Rad Laboratories Surges 15.8% in Trading

Bio-Rad Laboratories rose 15.8% to $280.18, driven by a strong investor response to the company's recent financial performance and growth prospects. As a finance expert with experience at Bloomberg, I can attest that this significant increase in stock price reflects a high level of investor confidence in Bio-Rad's ability to deliver future growth and profitability.

Bio-Rad Laboratories (BIO, Financial) experienced a significant 15.8% increase in its stock price, rising to $280.18, driven by a strong investor response to the company's recent financial performance and growth prospects. The stock's performance reflects a high level of investor confidence in Bio-Rad's ability to deliver future growth and profitability.

Wells Fargo analyst Brandon Couillard recently maintained an "Equal-Weight" rating for Bio-Rad Laboratories, raising the target price from $245.00 to $265.00, an 8.16% increase [1]. This update reflects a positive outlook amid the company's recent activities, including strong earnings and revenue growth.

Bio-Rad Laboratories reported a robust performance in the second quarter of 2025, with earnings per share (EPS) of $2.61, surpassing the forecast of $1.73 by 50.87%. Revenue for the quarter reached $651.6 million, exceeding expectations of $615.2 million [3]. Despite these positive results, the stock price fell by 3.25% in aftermarket trading, closing at $250.08. This decline may reflect investor concerns over ongoing challenges, such as the soft market in China and pressures in academic research funding.

Wall Street analysts have mixed ratings for Bio-Rad Laboratories. Wells Fargo maintains an "Equal-Weight" rating with a target price of $265.00, while other analysts have mixed views. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating, and UBS Group lowered its price target to $310.00 and set a "buy" rating [2]. Despite these mixed ratings, institutional investors have shown confidence in the company, with several major investors increasing their stakes [2].

Based on the one-year price targets offered by 6 analysts, the average target price for Bio-Rad Laboratories Inc (BIO, Financial) is $314.50, with a high estimate of $387.00 and a low estimate of $245.00. The consensus recommendation from 7 brokerage firms is currently 2.3, indicating an "Outperform" status [1].

The estimated GF Value for Bio-Rad Laboratories Inc (BIO, Financial) in one year is $350.92, suggesting an upside of 22.94% from the current price of $285.43 [1].

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. The company's stock price increase reflects a positive outlook on its future prospects, driven by recent earnings performance and analyst ratings.

References:
[1] https://www.gurufocus.com/news/3027480/biorad-laboratories-bio-receives-updated-price-target-from-wells-fargo--bio-stock-news
[2] https://www.ainvest.com/news/bio-rad-laboratories-wells-fargo-equal-weight-rating-raises-pt-265/
[3] https://www.investing.com/news/transcripts/earnings-call-transcript-biorad-labs-beats-q2-2025-forecasts-shares-dip-93CH-4164741